Tag: NTI
Neurotech to treat autism, epilepsy and ADHD using Dolce Cann’s proprietary cannabis strains
Neurotech International (ASX: NTI) has collared an exclusive global licence to use Dolce Cann Global’s cannabis strains to treat autism, epilepsy and ADHD.
Dolce is an Australian based medicinal ca...
Neurotech launches pilot virtual clinic for autism patients and their carers
Medical solutions developer Neurotech International (ASX: NTI) has launched a pilot version of a virtual clinic which enables doctors to interact with autism patients and remotely monitor their progre...
Neurotech International reports positive results in autism clinical trial
Perth-based medical solutions company Neurotech International (ASX: NTI) has confirmed its Mente Autism device specifically developed for children with autism is capable of producing significant posit...
Neurotech on course to alleviate autism effects for growing number of children
Medical solutions developer Neurotech International (ASX: NTI) has received an academia-fuelled boost for its ‘Mente Autism’ device, designed to improve cognitive functions in autistic children.
Th...
Neurotech International reports ‘excellent’ early findings for autism research
Perth-based Neurotech International (ASX: NTI) has surfaced from a trading halt with news of “excellent preliminary findings” for its Mente Autism device.
The medical solutions developer reported t...
